D
Tenaya Therapeutics, Inc. TNYA
$1.22 -$0.06-4.69% NASDAQ
Recommendation
Prev Close
$1.28
Volume
25
Avg Vol (90D)
3,713,234
Market Cap
$213.13M
Dividend & Yield
--
52-Week Range
$0.36 - $4.01
P/E (TTM)
--
EPS (TTM)
-$0.79
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Top 3 Insider Stock Buys in March—Are They Still Good in April?
3/25/2025 - MarketBeat
LifeSci Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)
11/15/2025 - TipRanks Financial Blog
Chardan Capital Issues Optimistic Forecast for TNYA Earnings
11/15/2025 - MarketBeat
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call - Slideshow
11/14/2025 - SeekingAlpha
Tenaya Therapeutics (NASDAQ:TNYA) Releases Quarterly Earnings Results
11/12/2025 - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Receives Buy Rating from Chardan Capital
11/11/2025 - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Releases Quarterly Earnings Results
11/11/2025 - Ticker Report
Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)
11/11/2025 - TipRanks Financial Blog
Tenaya Therapeutics (TNYA) Retains 'Buy' Rating with $9 Target Price TNYA Stock News
11/10/2025 - GuruFocus
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript
11/10/2025 - SeekingAlpha
Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript
11/10/2025 - Seeking Alpha: Transcripts
Tenaya Therapeutics reports Q3 EPS (12c), consensus (15c)
11/10/2025 - The Fly
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/10/2025 - GuruFocus
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/10/2025 - Globe Newswire
fda puts tenaya heart disease gene therapy clinical trial hold
11/10/2025 - FierceBiotech.com - Biotech
Tenaya Therapeutics (TNYA) Shares Promising Interim Trial Data at AHA 2025
11/9/2025 - GuruFocus
Tenaya Therapeutics presents new interim safety, efficacy data on TN-201
11/9/2025 - TipRanks Financial Blog
Tenaya Therapeutics presents new interim safety, efficacy data on TN-201
11/9/2025 - The Fly
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Moderate Buy" from Analysts
11/9/2025 - MarketBeat
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK -1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
11/8/2025 - Globe Newswire
Tenaya Therapeutics (TNYA) Stock Drops 16% After FDA Trial Hold
11/7/2025 - GuruFocus
Tenaya Therapeutics falls after FDA clinical hold on heart disorder trial
11/7/2025 - Seeking Alpha - Healthcare
Tenaya Therapeutics (NASDAQ:TNYA) Stock Price Down 2.2% - Time to Sell?
11/7/2025 - MarketBeat
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in ...
11/4/2025 - GuruFocus
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in ...
11/4/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$88.51M
EBIT (TTM)
-$97.21M
Net Income (TTM)
-$94.26M
Balance Sheet
Total Assets (Q)
$104.98M
Total Debt (Q)
$11.53M
Total Liabilities (Q)
$22.11M
Book Value Per Share (Q)
$0.5061
Cash Flow
Cash from Operations (TTM)
-$72.71M
Cash from Investing (TTM)
$70.25M
Cash from Financing (TTM)
$50.54M
Net Change in Cash (TTM)
$48.08M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
2.18
7-Day Total Return
5.17%
30-Day Total Return
-38.07%
60-Day Total Return
-12.86%
90-Day Total Return
46.42%
Year to Date Total Return
-14.08%
1-Year Total Return
-65.92%
2-Year Total Return
-38.69%
3-Year Total Return
-50.81%
5-Year Total Return
--
52-week Low
May 13, 2025 - $0.36
52-week High
Dec 10, 2024 - $4.01
Valuation
Market Cap
$213.13M - Micro Cap
Enterprise Value
$168.34M
Price/Sales (TTM)
--
Price/Book (Q)
2.53
Dividends and Shares
Shares Outstanding
163.35
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tenayatherapeutics.com
Phone Number
650 825 6990
Address
171 Oyster Point Boulevard
South San Francisco, CA 94080
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed